Navigation Links
Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
Date:12/14/2011

SAN DIEGO, Dec. 14, 2011 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer.  Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May 1996 to November 2003.  Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003, Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005.

"Fate's lead therapeutic, ProHema, has already demonstrated potential benefit to patients that are stricken with life-threatening hematologic malignancies and are in need of hematopoietic reconstitution.  I am excited to shepherd ProHema's further clinical development and its access to patients," said Dr. Rastetter.  "I am also impressed with Fate's approach to identifying therapeutic intervention points in adult stem cell biology, which has translated into a promising pipeline of product candidates.  I look forward to collaborating with the Fate team and board of directors to continue to drive forward in the development of innovative regenerative medicines."

Fate Therapeutics announced yesterday promising clinical results from a Phase 1b trial of ProHema as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.  The data were presented at the 53rd annual American Society of Hematology (ASH) meeting.  Of the twelve subjects that received ProHema, the median time to neutrophil recovery (> 500 cells/uL) was 17.5 days, which compares favorably to historical norms for patients undergoing double-UCB.  In addition, ProHema provided the dominant source of hematopoiesis in ten of the twelve subjects, suggesting that treatment with ProHema may confer preferential engraftment.'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin
2. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
5. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
6. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
7. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
8. Aratana Therapeutics Completes $15 Million Series B Financing
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced ... Nexera-i, adding to the company’s extensive line-up of ... intuitive operating environment, and full automation, the i-Series ... for conventional to ultra-high-speed analysis. , ... design so users can begin building the lab ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... live during the 10th Annual BIO CEO & ... p.m. Eastern Time., The presentation will be ... access the live presentation via the Web, please ...
... to Manufacture ARIUS, Product Candidate Trop-2 Signal ... ... Pharma, Inc., a full-,service biopharmaceutical development and protein production company, ... agreement,with ARIUS Research, Inc., a biotechnology company focused on discovering,and ...
... Precision and ... Simultaneous Diagnostic Monitoring MUKILTEO, Wash. and ... CBMX ) and Clarient, Inc. (Nasdaq: CLRT ),today jointly ... novel genomics-based cancer test called HemeScan(TM), a,comprehensive test related to ...
Cached Biology Technology:Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 2CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 5CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 6
(Date:8/20/2014)... Issue Serious allergic reactions to food often ... some children.    What you should know ... and this number may be increasing, especially among children. Up ... food allergies.  The symptoms of allergic reactions ... difficulties and loss of consciousness. Symptoms can also develop at ...
(Date:8/20/2014)... National Institutes of Health has awarded the Oklahoma Medical ... its research on anthrax and the bacteria,s effects on ... Coggeshall, Ph.D., and his colleagues have studied the human ... Cooperative Centers for Human Immunology. The original funding came ... on the heels of the terrorist attacks of Sept. ...
(Date:8/20/2014)... Wu Feng has built upon a National Science Foundation ... Cloud" program, and synergistically complemented it with subsequent collaborative ... Force on "big computing" for mini-drones and a $1 ... Health on "big data" for the life sciences. , ... each grant, he was able to tell a much ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... Prof. Nathan Nelson of Tel Aviv University,s Department ... has been awarded the 2012 Israel Prize in the ... in Jerusalem on the eve of Israel,s Independence Day ... molecular biology, Prof. Nelson is internationally renowned for his ...
... soon become a thing of the past. Instead, with ... painless injection four times a year would be enough. ... and is delivered by an injection into the outer layer ... The nanocarrier will then slowly release the drug over ...
... receive this year,s Charles Rodolphe Brupbacher Prize for Cancer ... of chronic inflammation in the development of tumors. The ... considered one of the highest accolades for cancer researchers ... Thursday in the framework of an international symposium on ...
Cached Biology News:NTU launches new centre to develop new eye-deas for occular therapeutics 2NTU launches new centre to develop new eye-deas for occular therapeutics 3Brupbacher Prize goes to cancer researcher Michael Karin 2
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: